Details for Patent: 7,943,582
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 7,943,582 protect, and when does it expire?
Patent 7,943,582 protects INVOKAMET XR, INVOKAMET, and INVOKANA, and is included in three NDAs.
This patent has forty-nine patent family members in thirty-eight countries.
Summary for Patent: 7,943,582
Title: | Crystalline form of 1-(.beta.-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Abstract: | A novel crystal form of 1-(.beta.-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethy- l]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum. |
Inventor(s): | Nomura; Sumihiro (Osaka, JP), Kawanishi; Eiji (Osaka, JP) |
Assignee: | Mitsubishi Tanabe Pharma Corporation (Osaka-Shi, JP) |
Application Number: | 11/987,670 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,943,582 |
Patent Claim Types: see list of patent claims | Compound; Process; Composition; Use; |
Drugs Protected by US Patent 7,943,582
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Pharms | INVOKAMET XR | canagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205879-002 | Sep 20, 2016 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | TREATMENT OF TYPE 2 DIABETES MELLITUS | See Plans and Pricing | ||
Janssen Pharms | INVOKAMET XR | canagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205879-002 | Sep 20, 2016 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS | See Plans and Pricing | ||
Janssen Pharms | INVOKAMET XR | canagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205879-002 | Sep 20, 2016 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS | See Plans and Pricing | ||
Janssen Pharms | INVOKAMET XR | canagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205879-001 | Sep 20, 2016 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS | See Plans and Pricing | ||
Janssen Pharms | INVOKAMET XR | canagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205879-001 | Sep 20, 2016 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS | See Plans and Pricing | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,943,582
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Japan | 2006-327019 | Dec 04, 2006 |
International Family Members for US Patent 7,943,582
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 064099 | See Plans and Pricing | |||
Argentina | 107510 | See Plans and Pricing | |||
Argentina | 118450 | See Plans and Pricing | |||
Australia | 2007329895 | See Plans and Pricing | |||
Brazil | PI0718882 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |